These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 23226652)

  • 21. Does low pentraxin-3 levels associate with polycystic ovary syndrome and obesity?
    Sahin FK; Sahin SB; Balik G; Ural UM; Tekin YB; Cure MC; Senturk S; Yuce S; Cure E
    Int J Clin Exp Med; 2014; 7(10):3512-9. PubMed ID: 25419391
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High sensitive serum C-reactive protein and its relationship with other cardiovascular risk factors in normoinsulinemic polycystic ovary patients without metabolic syndrome.
    Verit FF
    Arch Gynecol Obstet; 2010 Jun; 281(6):1009-14. PubMed ID: 19771438
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Polycystic ovary syndrome and obesity do not affect vascular parameters related to early atherosclerosis in young women without glucose metabolism disturbances, arterial hypertension and severe abnormalities of lipid profile.
    Barcellos CR; Lage SH; Rocha MP; Hayashida SA; Baracat EC; Romano A; Brito VN; Marcondes JA
    Gynecol Endocrinol; 2013 Apr; 29(4):370-4. PubMed ID: 23327607
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Carotid intima-media thickness in mainly non-obese women with polycystic ovary syndrome and age-matched controls.
    Kim JJ; Choi YM; Kang JH; Hwang KR; Chae SJ; Kim SM; Ku SY; Kim SH; Kim JG; Moon SY
    Obstet Gynecol Sci; 2013 Jul; 56(4):249-55. PubMed ID: 24328010
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association between circulating neuregulin 4 levels and metabolic, aterogenic, and AMH profile of polycystic ovary syndrome.
    Kurek Eken M; Sahin Ersoy G; Yayla Abide C; Sanverdi İ; Devranoglu B; Kutlu T; Çevik Ö
    J Obstet Gynaecol; 2019 Oct; 39(7):975-980. PubMed ID: 31064233
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased adipsin is associated with carotid intima media thickness and metabolic disturbances in polycystic ovary syndrome.
    Gursoy Calan O; Calan M; Yesil Senses P; Unal Kocabas G; Ozden E; Sari KR; Kocar M; Imamoglu C; Senses YM; Bozkaya G; Bilgir O
    Clin Endocrinol (Oxf); 2016 Dec; 85(6):910-917. PubMed ID: 27434652
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association of clinical androgen excess with radial artery intima media thickness in women with polycystic ovary syndrome.
    Yilmaz SA; Kebapcilar A; Koplay M; Kerimoglu OS; Pekin AT; Gencoglu B; Dogan NU; Celik C
    Gynecol Endocrinol; 2015 Jun; 31(6):477-82. PubMed ID: 26213862
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The evaluation of endothelial function with flow-mediated dilatation and carotid intima media thickness in young nonobese polycystic ovary syndrome patients; existence of insulin resistance alone may not represent an adequate condition for deterioration of endothelial function.
    Arikan S; Akay H; Bahceci M; Tuzcu A; Gokalp D
    Fertil Steril; 2009 Feb; 91(2):450-5. PubMed ID: 18501898
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effect of PCOS status on atherosclerosis markers and cardiovascular disease risk factors in young women with vitamin D deficiency.
    Atasayan K; Yoldemir T
    Gynecol Endocrinol; 2021 Mar; 37(3):225-229. PubMed ID: 32996333
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Visceral adiposity index levels in overweight and/or obese, and non-obese patients with polycystic ovary syndrome and its relationship with metabolic and inflammatory parameters.
    Durmus U; Duran C; Ecirli S
    J Endocrinol Invest; 2017 May; 40(5):487-497. PubMed ID: 27838846
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Thrombin-activatable fibrinolysis inhibitor and cardiovascular risk factors in polycystic ovary syndrome.
    Erdoğan M; Karadeniz M; Alper GE; Tamsel S; Uluer H; Cağlayan O; Saygili F; Yilmaz C
    Exp Clin Endocrinol Diabetes; 2008 Mar; 116(3):143-7. PubMed ID: 18350479
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum paraoxonase 1 activity, asymmetric dimethylarginine levels, and brachial artery flow-mediated dilatation in women with polycystic ovary syndrome.
    Soyman Z; Noyan V; Tulmac M; Yucel A; Sagsoz N; Bayrak T; Bayrak A; Cakir E
    Fertil Steril; 2011 Mar; 95(3):1067-72. PubMed ID: 21193188
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Endothelial dysfunction in young women with polycystic ovary syndrome: relationship with insulin resistance and low-grade chronic inflammation.
    Tarkun I; Arslan BC; Cantürk Z; Türemen E; Sahin T; Duman C
    J Clin Endocrinol Metab; 2004 Nov; 89(11):5592-6. PubMed ID: 15531516
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Overweight women with polycystic ovary syndrome have evidence of subclinical cardiovascular disease.
    Meyer C; McGrath BP; Teede HJ
    J Clin Endocrinol Metab; 2005 Oct; 90(10):5711-6. PubMed ID: 16046590
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Central arterial stiffness and diastolic dysfunction are associated with insulin resistance and abdominal obesity in young women but polycystic ovary syndrome does not confer additional risk.
    Rees E; Coulson R; Dunstan F; Evans WD; Blundell HL; Luzio SD; Dunseath G; Halcox JP; Fraser AG; Rees DA
    Hum Reprod; 2014 Sep; 29(9):2041-9. PubMed ID: 25035436
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of early atherosclerotic findings in women with polycystic ovary syndrome.
    Mohammadi A; Aghasi M; Jodeiry-Farshbaf L; Salary-Lac S; Ghasemi-Rad M
    J Ovarian Res; 2011 Oct; 4(1):19. PubMed ID: 22024243
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The cardiovascular risk profile of middle-aged women with polycystic ovary syndrome.
    Meun C; Gunning MN; Louwers YV; Peters H; Roos-Hesselink J; Roeters van Lennep J; Rueda Ochoa OL; Appelman Y; Lambalk N; Boersma E; Kavousi M; Fauser BC; Laven JS;
    Clin Endocrinol (Oxf); 2020 Feb; 92(2):150-158. PubMed ID: 31638273
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A comprehensive assessment of endothelial function in overweight women with and without polycystic ovary syndrome.
    Moran LJ; Hutchison SK; Meyer C; Zoungas S; Teede HJ
    Clin Sci (Lond); 2009 May; 116(10):761-70. PubMed ID: 18851710
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Spectrum of metabolic dysfunction in relationship with hyperandrogenemia in obese adolescent girls with polycystic ovary syndrome.
    Alemzadeh R; Kichler J; Calhoun M
    Eur J Endocrinol; 2010 Jun; 162(6):1093-9. PubMed ID: 20371657
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Alteration of cardiovascular risk parameters in women with polycystic ovary syndrome who were prescribed to ethinyl estradiol-cyproterone acetate.
    Gode F; Karagoz C; Posaci C; Saatli B; Uysal D; Secil M; Akdeniz B
    Arch Gynecol Obstet; 2011 Oct; 284(4):923-9. PubMed ID: 21140159
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.